Welcome to our dedicated page for Twist Bioscience news (Ticker: TWST), a resource for investors and traders seeking the latest updates and insights on Twist Bioscience stock.
Twist Bioscience Corporation reports developments in synthetic biology built around its silicon-based DNA synthesis platform. Company updates cover synthetic DNA tools and services for diagnostics, therapeutics, industrial, agriculture and research markets, including oligos, genes, proteins, libraries, characterization data, antibody discovery solutions and NGS workflow tools.
Recurring announcements include fiscal results, business updates, product launches such as expanded clonal gene capabilities and library preparation kits, antibody discovery licensing, investor presentations and Nasdaq inducement equity awards for new employees.
Twist Bioscience Corporation (NASDAQ: TWST) announced the launch of its integrated offering of antibody discovery services, combining its synthetic libraries, AI machine learning, and in vivo immunization through the acquisition of Abveris. This premium service aims to provide optimized, development-ready antibody candidates, enhancing throughput and speed for clients. The initiative is led by Tracey Mullen, newly appointed Senior VP of Biopharma. The offering will be showcased at the Festival of Biologics from March 20-22, 2023. The integrated approach facilitates improved discovery and optimization of diverse antibody formats, promoting success in preclinical development.
Twist Bioscience Corporation (NASDAQ: TWST) announced key presentations by CEO Emily M. Leproust and CFO Jim Thorburn at upcoming investor conferences. They will participate in the Cowen 43rd Annual Healthcare Conference on March 6-7, 2023, with a fireside chat on March 7 at 1:30 p.m. ET. The Barclays Global Healthcare Conference will occur on March 14, 2023, featuring a fireside chat at 2:05 p.m. ET. Both events will be webcasted live and available for replay for 30 days. Twist Bioscience specializes in synthetic DNA manufacturing, with applications across healthcare, agriculture, and more.
Twist Bioscience Corporation (NASDAQ: TWST) announced the discovery of alpaca-derived VHH antibodies via a novel in vivo screening method on the Beacon platform. The study, published in BioRxiv, showcases methodology that efficiently screens single B cells for specific heavy-chain-only antibodies, particularly targeting human prostate specific membrane antigen (PSMA). All VHH-Fc candidates demonstrated nanomolar affinity for PSMA. This approach allows for improved antibody optimization and potential therapeutic applications, leveraging Twist's advanced sequencing technologies.
Twist Bioscience (NASDAQ: TWST) announced early access to its enhanced Whole Genome Sequencing (eWGS) solution for non-human genomics at the AGBT 2023 meeting in Hollywood, Florida. This innovative solution allows researchers to obtain simultaneous low-pass whole genome data with deep coverage of specific regions, enhancing cost-effectiveness and high throughput. The eWGS workflow uses a modified 96-plex library preparation kit, facilitating the sequencing of 96 samples in a single tube, aimed at improving resolution and flexibility in agricultural genomics. Additionally, Twist will present three posters on next-generation sequencing and reference standards during the conference.
Twist Bioscience Corporation (NASDAQ: TWST) reported a strong start to fiscal 2023, with revenue of $54.2 million in the first quarter, reflecting a 29% increase from $42.0 million in the same quarter last year. Total orders rose to $64.7 million, a 30% increase year-over-year. Despite a net loss of $41.8 million, improvements were noted in expenses: Selling, General and Administrative costs dropped from $51.1 million to $42.3 million. The company shipped products to 2,060 customers and launched key partnerships in biopharma and DNA storage, showcasing robust growth and innovation in its core business areas.
Twist Bioscience Corporation (NASDAQ: TWST) announced the shipment of initial products from its new manufacturing facility in location value="LU/us.or.willle"Wilsonville, Oregon, known as the Factory of the Future. This 110,000 square-foot facility is expected to double the company's manufacturing capacity, supporting substantial growth in production and revenue. CEO Emily M. Leproust expects the enhanced capacity will facilitate new product introductions, including 'fast genes' that promise quicker manufacturing turnaround times. Currently, the company offers turnaround times of 10 business days for clonal genes and 5 business days for gene fragments and oligo pools.
Twist Bioscience Corporation (NASDAQ: TWST) will release its fiscal 2023 Q1 financial results on February 3, 2023, before market opening. A conference call and live audio webcast will follow at 8:00 a.m. ET, aimed at discussing the results and providing business updates. The press release with details will be available on Twist's Investor Relations page.
Twist is a leader in synthetic biology and genomics, utilizing a cutting-edge DNA synthesis platform built on silicon technology, serving various sectors including healthcare and agriculture.
Twist Bioscience (TWST) and Centogene (CNTG) have launched three next-generation sequencing target enrichment panels aimed at advancing research and diagnostics for rare diseases and hereditary cancers. These panels enhance the precision of genetic sequencing and are based on data from Centogene's Biodatabank, which includes nearly 700,000 patients. The products include the Twist Alliance CNTG Exome Panel, CNTG Rare Disease Panel, and CNTG Hereditary Oncology Panel. This collaboration is expected to improve diagnostic capabilities worldwide, facilitating earlier disease detection and treatment development.
Twist Bioscience (NASDAQ: TWST) has announced a research collaboration with Astellas Pharma Inc to discover antibodies targeting diseases with high unmet medical needs. This partnership, following a successful initial collaboration, highlights Twist's antibody discovery capabilities through its Library of Libraries. Under the agreement, Twist will receive an upfront payment, project-specific research fees, and earn up to $11 million USD per product for clinical milestones, along with royalties on product sales. Astellas will handle product development and commercialization.
Twist Bioscience Corporation (NASDAQ: TWST) announced that CEO and co-founder Emily M. Leproust, Ph.D., will present at the 41st Annual J.P. Morgan Health Care Conference on January 9th at 5:15 p.m. PST. The live presentation will be webcast and accessible via the company's investor relations page. A replay will be available for 30 days post-event. Twist Bioscience specializes in synthetic DNA production using its proprietary silicon platform to create products for various sectors including healthcare and agriculture.